Value
9.0/10data confidence 33%| Component | Sub-score |
|---|---|
| Analyst target | 9.0 |
- ▸Attractively valued
SGP · Why this verdict
Why SpyGlass Pharma (SGP) is rated SELL
Updated
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results.
Show full disclosure ▾Hide full disclosure ▴
About TrendMatrix. TrendMatrix is a publisher of general securities research and market commentary. We publish on a regular schedule. All content is the same for every subscriber in a tier — we do not provide personalized investment advice and we do not take into account any individual subscriber's financial situation, investment objectives, risk tolerance, tax situation, or holdings.
Not investment advice. TrendMatrix is not a registered investment adviser. Our content is for informational and educational purposes only. Consult your own licensed investment adviser, broker, or tax professional before making any investment decision.
Conflicts and positions. The TrendMatrix editorial team frequently holds personal long-term positions in securities discussed. We disclose positions held at the time of publication on each piece. We maintain a trading-window policy: we do not initiate or close positions in the same direction as a TrendMatrix publication within 24 hours before or 72 hours after publication.
No paid promotion. TrendMatrix does not accept payment from any issuer, broker, or third party in exchange for coverage of any security. Our sole compensation is subscription revenue.
No fiduciary duty. No fiduciary, advisory, or agency relationship is created between you and TrendMatrix by reading our content or subscribing to our service.
Performance. Past performance is not indicative of future results. Performance figures reflect the published model only and do not reflect any individual subscriber's actual results.
VerdictSELL
Overall score5.2/10
ConfidenceMEDIUM
MacroNEUTRAL
Thesis pillars
| Pillar | Expectation | Trend |
|---|---|---|
The most recent quarter missed estimates by a wide margin, with a -91.7% earnings surprise. Earnings | The company should post a smaller miss or a beat (surprise above -20%) at its next report in roughly 40 days. | →Stable |
| CounterA single-quarter miss of this magnitude at a pre-revenue biotech is often driven by one-time R&D expense timing rather than a structural deterioration. | ||
SpyGlass Pharma carries substantial modeled upside, with the sentiment dimension citing 135% analyst upside and an overall asymmetry ratio of 6.96 driving a 104% price target. Sentiment breakdown | Analyst upside should compress toward 60-80% over the next 12 months as the price converges toward consensus targets, or targets should be reaffirmed at current elevated levels. | →Stable |
| CounterExtreme modeled upside on a thinly covered biotech with a recent large earnings miss often reflects a stale or overly optimistic single analyst target rather than genuine mispricing. | ||
The business shows no competitive moat and general quality concerns, keeping the quality score at just 2.4/10. Quality breakdown | The overall quality score should rise above 4.0 and moat characteristics should improve over the next several quarters. | →Stable |
| CounterEarly-stage biotechs are frequently pre-commercial and structurally lack a moat, making this metric less predictive of the pipeline's ultimate value. | ||
Price momentum has failed the engine's threshold at 3.9, with falling on-balance volume signaling distribution. Momentum breakdown | Momentum score should rise above 4.5 and on-balance volume should turn positive over the next quarter to confirm a trend reversal. | →Stable |
| CounterNegative momentum in a small speculative biotech can reverse abruptly on a single clinical or regulatory catalyst, making current technicals a weak predictor. | ||
The most recent quarter missed estimates by a wide margin, with a -91.7% earnings surprise.
→StableEarnings
- Expectation
- The company should post a smaller miss or a beat (surprise above -20%) at its next report in roughly 40 days.
CounterA single-quarter miss of this magnitude at a pre-revenue biotech is often driven by one-time R&D expense timing rather than a structural deterioration.
SpyGlass Pharma carries substantial modeled upside, with the sentiment dimension citing 135% analyst upside and an overall asymmetry ratio of 6.96 driving a 104% price target.
→StableSentiment breakdown
- Expectation
- Analyst upside should compress toward 60-80% over the next 12 months as the price converges toward consensus targets, or targets should be reaffirmed at current elevated levels.
CounterExtreme modeled upside on a thinly covered biotech with a recent large earnings miss often reflects a stale or overly optimistic single analyst target rather than genuine mispricing.
The business shows no competitive moat and general quality concerns, keeping the quality score at just 2.4/10.
→StableQuality breakdown
- Expectation
- The overall quality score should rise above 4.0 and moat characteristics should improve over the next several quarters.
CounterEarly-stage biotechs are frequently pre-commercial and structurally lack a moat, making this metric less predictive of the pipeline's ultimate value.
Price momentum has failed the engine's threshold at 3.9, with falling on-balance volume signaling distribution.
→StableMomentum breakdown
- Expectation
- Momentum score should rise above 4.5 and on-balance volume should turn positive over the next quarter to confirm a trend reversal.
CounterNegative momentum in a small speculative biotech can reverse abruptly on a single clinical or regulatory catalyst, making current technicals a weak predictor.
TrendMatrix Research · core thesis
Engine thesis — one sentence
SpyGlass Pharma offers substantial analyst-implied upside (135%, a 6.96 asymmetry ratio) but is weighed down by weak fundamental quality, no competitive moat, negative price momentum, and a sharp recent earnings miss of -91.7%, keeping the stock below the quality floor despite its speculative upside case.
Falsifiable statement — pillar-level invalidators below. Engine-derived; not personalized advice.
Per-dimension breakdown
Quality
2.5/10data confidence 86%| Component | Sub-score |
|---|---|
| Gross margin | 0.0 |
| Op margin | 0.0 |
| Net margin | 0.0 |
| Current ratio | 5.0 |
| Moat | 5.5 |
| Piotroski F | 4.4 |
- ▸Quality concerns
Growth
5.0/10data confidence 50%Momentum
5.2/10data confidence 100%| Component | Sub-score |
|---|---|
| RSI | 3.7 |
| MACD | 9.5 |
| OBV | 5.4 |
| MA position | 5.5 |
| Volume | 2.1 |
Sentiment
6.6/10data confidence 100%| Component | Sub-score |
|---|---|
| Analyst rating | 5.0 |
| Price target | 10.0 |
| erm sentiment | 5.0 |
- ▸Analyst upside: 120%
Insider
5.0/10data confidence 50%Peer rank
5.9/10data confidence 80%| Component | Sub-score |
|---|---|
| value rank | 5.0 |
| quality rank | 5.0 |
| growth rank | 5.0 |
- ▸Conservative debt levels
Technical
3.1/10data confidence 100%| Component | Sub-score |
|---|---|
| bollinger | 2.7 |
| support resistance | 4.1 |
| 52w position | 2.6 |
Risk (lower is worse)
3.9/10data confidence 80%| Component | Sub-score |
|---|---|
| short interest | 5.4 |
| days to cover | 0.0 |
| volatility | 0.0 |
| debt equity | 10.0 |
- ▸Concentration risks: 1 HIGH (10-K Item 1A — sized via position_sizing, validated via buy_confidence)
Catalyst
2.5/10data confidence 100%| Component | Sub-score |
|---|---|
| erm | 5.0 |
| earnings history | 0.0 |
| earnings timing | 5.0 |
| surprise avg | 0.0 |
How the verdict was assembled
Engine trigger
Quality below minimum threshold.
Engine technical detail
verdict_path:
L1:HARD_BLOCKPassed (8)
- MOMENTUM:5.2>=4.5
- ASYMMETRY:6.1>=1.5
- INSIDER:OK
- 8K:CLEAN
- NEWS_EVENTS:NONE_RECENT
- EARNINGS_PROXIMITY:37d clear
- SEMI_CYCLE_PEAK:CLEAR
- MATERIALS_CYCLE_PEAK:CLEAR
Failed (0)
none
Warning (1)
- MOMENTUM:5.2<5.5 (soft — BUY_NOW allowed but watch)
Reward-to-Risk
6.09
Upside
+91.3%
Downside
15.0%
Sizing output
AVOID
Setup— — No clear chart pattern; technical signals are mixed
EdgeInst Constrain — Small cap ($0.6B) below institutional reach
SuitabilitySpeculative — Binary industry: Biotechnology
Investment implication
The L1 gate blocked the positive-verdict path: a hard-floor threshold was breached, so dimensional pillars — including Value at 9.0 could not lift the engine output above the verdict floor.
The strongest dimensions are Value at 9.0, Sentiment at 6.6, and Peer rank at 5.9; the weakest are Catalyst at 2.5, Quality at 2.5, and Technical at 3.1. The V9 engine cleared all gates with 1 warning, producing an asymmetric reward-to-risk of 6.09 and an engine sizing output of AVOID.
What would invalidate the thesis
Falsifying conditions — when triggered, the corresponding pillar's thesis is invalidated.
- P1Deep Analyst Implied Upside
Trip ifAnalyst upside compresses below 50% from the current 135% without at least a 40% price increase.
- P2Weak Quality No Moat
Trip ifThe overall quality score stays below 2.0 for 2 more consecutive quarters, or the moat score stays below 5.0.
- P3Negative Price Momentum
Trip ifThe momentum score stays below 4.5 for 2 more consecutive months, confirming the current gate failure at 3.9.
- P4Large Recent Earnings Miss
Trip ifThe company posts a second consecutive earnings miss with a surprise below -20%.